arrow
E

Erik van Werkhoven

erasmus mc cancer institute
H指数:46
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-R

Nivolumab巩固治疗在完成DA-EPOCH-R方案后达到完全代谢缓解的双打击和三打击高危B细胞淋巴瘤患者中的应用

2026-10-300
OAAI
Postoperative radiotherapy for oral cavity cancer with or without elective neck radiotherapy of the pN0 en bloc dissected neck: oncologic outcomes and late toxicity

口咽癌术后放疗联合或未联合对pN0整块切除颈部进行选择性颈部放疗:肿瘤学结果及晚期毒性

2025-07-010
PRE
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

HOVON 170 DLBCL-预期试验的原理和设计: 用右雷佐生预防蒽环类药物诱导的心功能障碍

2025-01-280
OAAI
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma
2024-07-040
OAAI
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS
2024-02-282
OAAI
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
2023-09-093
OA
A non-randomized risk-adjusted comparison of lenalidomide plus R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
2023-05-224
OAAI
Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study
2022-06-0119
OAAI